Pemazyre (pemigatinib) from Innovent Biologics is a novel treatment for cholangiocarcinoma, a type of bile duct cancer. The indication covers unresectable locally advanced or metastatic cholangiocarcinoma with a fibroblast growth factor receptor 2 (FGFR2) fusion or other rearrangement.
Innovent continues to roll the drug out throughout the world. In June, it won regulatory approval in Taiwan to treat adults with previously treated, unresectable locally advanced or metastatic cholangiocarcinoma. That approval also refers to cholangiocarcinoma with a FGFR2 fusion or rearrangement
Filed Under: Oncology